Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 18, 2026, titled "Zydus and Torrent Pharma sign licensing agreement to co-market innovative Semaglutide Injection in India".
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Zydus Lifesciences has signed a Licensing and Supply Agreement with Torrent Pharmaceuticals to co-market an innovative Semaglutide Injection (15 mg/3 ml) in India. Zydus developed the formulation in a prefilled cartridge with a reusable patient-friendly pen device and will handle manufacturing and supply. Torrent will co-market the product under the brand name SEMBOLIC™ with semi-exclusive rights, while Zydus will market it under SEMAGLYN™, MASHEMA™ and ALTERME™. Torrent will pay an upfront licensing fee to Zydus as part of the deal. The product targets adults with type 2 diabetes and chronic weight management, addressing a fast-growing GLP-1 therapy market in India.
Positive for Zydus as it adds a high-margin licensing revenue stream, widens reach of its Semaglutide portfolio through Torrent's large chronic-therapy field force, and validates its innovative drug-device platform. Investors may see this as a strategic commercial win without significant capital outlay.